MiMedx Group, Inc. (MDXG) Insider Trading Activity

NASDAQ$3.2266-0.02 (-0.62%)
Market Cap
$474.26M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
647 of 849
Rank in Industry
369 of 491

MDXG Insider Trading Activity

MDXG Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$432,329
1
100

Related Transactions

Maersk-Moller KimberlyChief Commercial Officer
0
$0
1
$432,329
$-432,329

About MiMedx Group, Inc.

MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among …

Insider Activity of MiMedx Group, Inc.

Over the last 12 months, insiders at MiMedx Group, Inc. have bought $0 and sold $432,329 worth of MiMedx Group, Inc. stock.

On average, over the past 5 years, insiders at MiMedx Group, Inc. have bought $648,074 and sold $1.06M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 200,000 shares for transaction amount of $1.27M was made by Capper Joseph H (Chief Executive Officer) on 2025‑05‑02.

List of Insider Buy and Sell Transactions, MiMedx Group, Inc.

2025-11-06SaleMaersk-Moller KimberlyChief Commercial Officer
58,300
0.0382%
$7.42
$432,329
-40.04%
2025-05-02PurchaseCapper Joseph HChief Executive Officer
200,000
0.1361%
$6.34
$1.27M
+5.46%
2025-03-17SaleMaersk-Moller KimberlyChief Commercial Officer
1,759
0.0012%
$8.04
$14,142
-15.42%
2025-03-13SaleHulse William Frank IVGeneral Counsel and CAO
54,596
0.037%
$7.89
$430,762
-13.81%
2025-03-13SaleMaersk-Moller KimberlyChief Commercial Officer
4,106
0.0028%
$7.89
$32,396
-13.81%
2025-03-10SaleHulse William Frank IVGeneral Counsel and CAO
81,446
0.0553%
$7.80
$635,279
-12.20%
2025-02-28SaleMaersk-Moller KimberlyChief Commercial Officer
2,111
0.0015%
$8.40
$17,743
-18.10%
2025-02-13SaleWhitlow Ricci SChief Operating Officer
61,420
0.0422%
$8.28
$508,558
-16.43%
2024-03-13SaleHulse William Frank IVGeneral Counsel and CAO
20,381
0.0139%
$7.95
$162,029
-8.30%
2024-02-20SaleWhitlow Ricci SChief Operating Officer
15,271
0.0131%
$8.01
$122,351
-9.33%
2024-02-16SaleWhitlow Ricci SChief Operating Officer
15,493
0.0133%
$8.07
$125,075
-9.55%
2024-02-15SaleWhitlow Ricci SChief Operating Officer
15,198
0.013%
$8.06
$122,496
-11.53%
2024-02-14SaleWhitlow Ricci SChief Operating Officer
15,845
0.0132%
$8.03
$127,267
-9.67%
2023-11-21PurchaseDOUG RICEChief Financial Officer
5,000
0.0043%
$7.16
$35,787
+1.25%
2023-06-23PurchaseCapper Joseph HChief Executive Officer
42,025
0.037%
$6.50
$273,331
+17.52%
2023-06-22PurchaseCapper Joseph HChief Executive Officer
57,975
0.0504%
$6.33
$367,104
+19.00%
2023-05-16SaleStein Robert BenjaminPresident, Regenerative Med.
10,365
0.009%
$5.95
$61,627
+25.71%
2023-05-15SaleStein Robert BenjaminPresident, Regenerative Med.
3,607
0.0032%
$6.15
$22,170
+23.93%
2023-05-10SaleCarlson Peter MChief Financial Officer
5,976
0.0051%
$5.93
$35,414
+23.68%
2023-05-10SaleHulse William Frank IVGeneral Counsel and CAO
5,870
0.005%
$5.93
$34,786
+23.68%
Total: 159
*Gray background shows transactions not older than one year

Insider Historical Profitability

33.64%
PETIT PARKER HChairman & CEO
5009121
3.4327%
$16.28M91
+25.79%
KOOB CHARLES Edirector
1312306
0.8993%
$4.26M31
+51.39%
Eichler Kurt Mdirector
574576
0.3937%
$1.87M20
Capper Joseph HChief Executive Officer
529530
0.3629%
$1.72M30
+13.99%
Taylor William CharlesPresident and COO
467424
0.3203%
$1.52M119
+61.76%
GORLIN STEVEdirector
451857
0.3096%
$1.47M299
+51.19%
MCCAW ROBERTA LGeneral Counsel and Secretary
193247
0.1324%
$628,052.7511
+85.11%
Rooke Andrew K. Jr.director
155166
0.1063%
$504,289.5010
PAPASAN LARRY Wdirector
127320
0.0872%
$413,790.0021
+51.39%
DOUG RICEChief Financial Officer
102200
0.07%
$332,150.0010
+1.25%
BLESER JOSEPH Gdirector
76085
0.0521%
$247,276.2540
<0.0001%
Culumber Michael J.Chief Financial Officer
42000
0.0288%
$136,500.0010
+69.23%
Haden Alexandra OGeneral Counsel & Secretary
40528
0.0278%
$131,716.0010
+12.23%
Evans Charles Robertdirector
31878
0.0218%
$103,603.5010
+6.06%
DEWBERRY J TERRYdirector
16666
0.0114%
$54,164.5010
YESTON NEILdirector
5000
0.0034%
$16,250.0010
+61.62%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$3,887,391
114
13.01%
$433.37M
$40,226,318
58
18.89%
$539.26M
$16,169,789
40
7.44%
$485.1M
$2,481,409
33
201.68%
$455.48M
$31,271,604
28
28.69%
$477.19M

MDXG Institutional Investors: Active Positions

Increased Positions111+42.05%10M+9.27%
Decreased Positions110-41.67%7M-6.84%
New Positions34New2MNew
Sold Out Positions25Sold Out927,444Sold Out
Total Postitions265+0.38%107M+2.42%

MDXG Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Essex Woodlands Management, Inc.$182,705.0019.05%28.2M00%2025-09-30
Blackrock, Inc.$73,370.007.65%11.32M-203,330-1.76%2025-09-30
Trigran Investments, Inc.$49,903.005.2%7.7M-689,430-8.22%2025-09-30
Vanguard Group Inc$44,075.004.6%6.8M-155,611-2.24%2025-09-30
First Light Asset Management, Llc$23,671.002.47%3.65M+2M+89.52%2025-09-30
State Street Corp$23,293.002.43%3.59M+128,693+3.71%2025-09-30
Geode Capital Management, Llc$18,429.001.92%2.84M+789+0.03%2025-09-30
Paradigm Capital Management Inc/Ny$17,180.001.79%2.65M-2M-40.45%2025-09-30
Dimensional Fund Advisors Lp$15,438.001.61%2.38M+99,084+4.34%2025-09-30
Cannell Capital Llc$13,050.001.36%2.01M-60,086-2.9%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.